Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs 10X Genomics Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.41 (market cap $746.48M), while 10X Genomics Inc trades at $84.49 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 13.5× Rex Fang & Innovation Equity Premium Income ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and 10X Genomics Inc for 92 Days on average.
| FEPI | TXG | |
|---|---|---|
Market Cap | $746.48M | $10.07B |
Volume | 334,337 | 5,657,286 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $97.74 |
52-Week Low | $37.98 | $11.48 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
